[go: up one dir, main page]

RU2018124601A3 - - Google Patents

Download PDF

Info

Publication number
RU2018124601A3
RU2018124601A3 RU2018124601A RU2018124601A RU2018124601A3 RU 2018124601 A3 RU2018124601 A3 RU 2018124601A3 RU 2018124601 A RU2018124601 A RU 2018124601A RU 2018124601 A RU2018124601 A RU 2018124601A RU 2018124601 A3 RU2018124601 A3 RU 2018124601A3
Authority
RU
Russia
Application number
RU2018124601A
Other versions
RU2741802C2 (ru
RU2018124601A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018124601A publication Critical patent/RU2018124601A/ru
Publication of RU2018124601A3 publication Critical patent/RU2018124601A3/ru
Application granted granted Critical
Publication of RU2741802C2 publication Critical patent/RU2741802C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716Muscle proteins, e.g. myosin, actin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018124601A 2016-01-12 2017-01-11 АНТИТЕЛО К Myl9 RU2741802C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016003429 2016-01-12
JP2016-003429 2016-01-12
PCT/JP2017/000605 WO2017122666A1 (ja) 2016-01-12 2017-01-11 抗Myl9抗体

Publications (3)

Publication Number Publication Date
RU2018124601A RU2018124601A (ru) 2020-02-14
RU2018124601A3 true RU2018124601A3 (ru) 2020-04-30
RU2741802C2 RU2741802C2 (ru) 2021-01-28

Family

ID=59311587

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018124601A RU2741802C2 (ru) 2016-01-12 2017-01-11 АНТИТЕЛО К Myl9

Country Status (14)

Country Link
US (1) US10513561B2 (ru)
EP (1) EP3404040B1 (ru)
JP (1) JP6872756B2 (ru)
KR (1) KR102800024B1 (ru)
CN (1) CN108431037B (ru)
AU (1) AU2017207082B2 (ru)
BR (1) BR112018013807A2 (ru)
CA (1) CA3008786A1 (ru)
ES (1) ES2913162T3 (ru)
IL (1) IL260083B2 (ru)
MA (1) MA43869A (ru)
MX (1) MX2018008358A (ru)
RU (1) RU2741802C2 (ru)
WO (1) WO2017122666A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220249509A1 (en) * 2019-07-05 2022-08-11 Icahn School Of Medicine At Mount Sinai Method for preventing hair loss
EP4244392A1 (en) * 2020-11-16 2023-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for predicting and treating uveal melanoma
WO2024080377A1 (ja) * 2022-10-14 2024-04-18 国立大学法人千葉大学 肺高血圧症の検出方法及び肺高血圧症の治療薬若しくは予防薬
CN118440198B (zh) * 2024-04-03 2024-11-15 武汉爱博泰克生物科技有限公司 抗人cd69蛋白的兔单克隆抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305811A1 (en) * 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
KR20080034995A (ko) 2005-08-09 2008-04-22 유니버시티 오브 버지니아 페이턴트 파운데이션 혈관 투과성을 저해하는 방법 및 조성물
JP4777785B2 (ja) * 2006-01-31 2011-09-21 独立行政法人科学技術振興機構 ケモカインレセプターccr5のn末端領域に対する抗体酵素
WO2008105058A1 (ja) * 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
NZ595825A (en) 2009-04-20 2012-10-26 Kyowa Hakko Kirin Co Ltd Antibody containing igg2 having amino acid mutation introduced therein
CA2759733C (en) * 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
WO2011016567A1 (ja) * 2009-08-07 2011-02-10 協和発酵キリン株式会社 抗アミロイドβオリゴマーヒト化抗体
CA2928851A1 (en) * 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
WO2014074847A1 (en) * 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
JP6403668B2 (ja) * 2013-05-30 2018-10-10 国立大学法人千葉大学 抗ミオシン調節軽鎖ポリペプチド抗体を含む炎症疾患治療用組成物
WO2014205501A1 (en) * 2013-06-27 2014-12-31 Monash University Il-21 binding proteins and uses thereof
EP3156072B1 (en) * 2014-06-11 2020-08-19 IDAC Theranostics, Inc. Method for reducing side effects of immune checkpoint control agent

Also Published As

Publication number Publication date
EP3404040A1 (en) 2018-11-21
RU2741802C2 (ru) 2021-01-28
MA43869A (fr) 2018-11-21
US10513561B2 (en) 2019-12-24
CA3008786A1 (en) 2017-07-20
IL260083A (en) 2018-07-31
EP3404040A4 (en) 2019-08-07
ES2913162T3 (es) 2022-05-31
IL260083B2 (en) 2023-09-01
US20190002588A1 (en) 2019-01-03
KR20180098570A (ko) 2018-09-04
EP3404040B1 (en) 2022-03-02
AU2017207082B2 (en) 2023-07-13
JPWO2017122666A1 (ja) 2018-11-01
BR112018013807A2 (pt) 2018-12-11
RU2018124601A (ru) 2020-02-14
AU2017207082A1 (en) 2018-07-05
MX2018008358A (es) 2018-09-21
KR102800024B1 (ko) 2025-04-28
WO2017122666A1 (ja) 2017-07-20
CN108431037B (zh) 2021-12-17
JP6872756B2 (ja) 2021-05-19
IL260083B1 (en) 2023-05-01
CN108431037A (zh) 2018-08-21

Similar Documents

Publication Publication Date Title
BR112019001667A2 (ru)
RU2018124601A3 (ru)
BR212018070320U2 (ru)
BR112018071172A2 (ru)
BE2016C036I2 (ru)
CN303537400S (ru)
CN303538706S (ru)
CN303535546S (ru)
CN303536049S (ru)
CN303536130S (ru)
CN303536205S (ru)
CN303536215S (ru)
CN303536239S (ru)
CN303536379S (ru)
CN303536489S (ru)
CN303536542S (ru)
CN303536549S (ru)
CN303536579S (ru)
CN303537691S (ru)
CN303536597S (ru)
CN303537551S (ru)
CN303537328S (ru)
CN303537330S (ru)
CN303538740S (ru)
CN303537415S (ru)